Fondaparinux was not inferior to unfractionated heparin for symptomatic pulmonary embolism

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p68
Academic Journal
This article presents a study, which states that in patients with symptomatic pulmonary embolism (PE), fondaparinux is noninferior to unfractionated heparin (UFH). 2213 patients, who had acute symptomatic PE and required antithrombotic therapy, were taken for the study. Exclusion criteria were receipt of low-molecular-weight heparin or oral anticoagulants greater than 24 hours; need for thrombolysis, embolectomy, or a vena cava filter; contraindication to anticoagulant therapy; serum creatinine level greater than 177. Composite endpoint of symptomatic recurrent venous thromboembolism, with 95% power to reject an absolute recurrence rate of 3.5% higher with fondaparinux than UFH.


Related Articles

  • Cancer and thrombosis: implications of published guidelines for clinical practice. Khorana, A. A. // Annals of Oncology;Oct2009, Vol. 20 Issue 10, p1619 

    Cancer is a frequent finding in patients with thrombosis, and thrombosis is much more prevalent in patients with cancer, with important clinical consequences. Thrombosis is the second most common cause of death in cancer patients. Venous thromboembolism (VTE) in cancer is also associated with a...

  • Trombosis de la arteria renal en un recién nacido. Presentación de un caso y revisión. Torres, Ana Lucía; Torres, Javier; Cifuentes, Jorge Andrés // Colombia Medica;ene-mar2009, Vol. 40 Issue 1, p114 

    This report describes a newborn who presents high pressure values and absence of pulses in inferior extremities in his 4th day of life. Posterior to placement of umbilical arterial catheter, confirming diagnostic of thrombosis in aorta and left renal artery. A gamagraphy with MAG 3 was performed...

  • Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer: COMMENTARY. Deitcher, Steven R. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p10 

    This article focuses on a study regarding low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism (VTE) in patients with cancer, published in the 2003 issue of "New England Journal of Medicine." In patients with cancer and VTE, long-term warfarin...

  • Postoperative Versus Preoperative Initiation of Deep-Vein Thrombosis Prophylaxis with a Low-Molecular-Weight Heparin (Nadroparin) in Elective Hip Replacement. Palareti, Gualtiero; Borghi, Battista; Coccheri, Sergio; Leali, Nicoletta; Golfieri, Rita; Montebugnoli, M.; Inghilleri, Giovanni; Ronzio, Alessandro; Barbui, Tiziano; Pogliani, Enrico Maria; Di Nino, Gianfranco; Spotorno, Lorenzo // Clinical & Applied Thrombosis/Hemostasis;Winter1996, Vol. 2 Issue 1, p18 

    The aim of this multicenter, randomized, double-blind study performed in patients undergoing elective hip surgery was to compare the efficacy and safety of prophylaxis with low-molecular-weight heparin (LMWH) (Nadroparin, 7,500 anti-Xa IC units for the first 3 days and 10,000 from the fourth day...

  • Prophylactic use of LMWH plus intermittent pneumatic compression prevented DVT in hip or knee arthroplasty. Eikelboom, John W. // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p48 

    The article cites a research study, which reveals that prophylactic use of low-molecular-weight heparin (LMWH) plus intermittent pneumatic compression prevented deep vein thrombosis (DVT) in hip or knee arthroplasty. The researchers concluded that in patients who have total hip or total knee...

  • SELF ASSESSMENT ANSWERS: Recurrent orogenital ulcers with papilloedema and headaches.  // Postgraduate Medical Journal;Jan2002, Vol. 78 Issue 915, p57 

    The article presents several question and answers related to recurrent orogenital ulcers with papilloedema and headaches. The probable complication of the initial diagnosis has occurred during dural sinus thrombosis. The major treatment of this complication is anticoagulation with heparin and...

  • Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism: Current Recommendations. Hull, Russell D.; Pineo, Graham F. // Clinical & Applied Thrombosis/Hemostasis;Apr1998, Vol. 4 Issue 2, p96 

    Pulmonary embolism remains a major cause of death in high-risk medical and surgical patients. This is unfortunate as effective measures for prevention of venous thromboembolism in such patients are now available. Based on Level 1 evidence from clincial trials and systematic reviews,...

  • Enoxaparin sodium/heparin.  // Reactions Weekly;12/13/2008, Issue 1232, p16 

    The article describes a case of heparin-induced thrombocytopenia associated with antiphospholipid antibody syndrome in a 49-year-old woman following anticoagulation with heparin and enoxaparin sodium. The patient received heparin and enoxaparin sodium for the treatment of deep vein thrombosis...

  • Enoxaparin sodium/heparin/nadroparin calcium.  // Reactions Weekly;1/31/2009, Issue 1237, p9 

    The article describes the cases of four patients who developed allergic contact dermatitis to enoxaparin sodium, heparin or nadroparin calcium. The patients subsequently demonstrated cross-reactivity to other heparins on skin testing. Patient 1 received heparin calcium during an episode of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics